Nontuberculous mycobacteria in solid organ transplant

Shweta Anjan, Michele I. Morris

Research output: Contribution to journalReview article

Abstract

Purpose of reviewNontuberculous mycobacteria (NTM) are emerging pathogens of concern especially in solid organ transplant candidates and recipients. This review aims to address diagnostic challenges, new and emerging treatment options, and infection prevention.Recent findingsThe incidence of NTM infections in transplant candidates and recipients is rising. The infection prevalence of these environmental pathogens varies geographically by species with a coastal predominance. Although existing guidelines from the American Thoracic Society, Infectious Diseases Society of America, and British Thoracic Society provide recommendations for diagnosis and management, they do not fully address the subtle nuances and challenges faced in managing infections in immunocompromised transplant recipients. Evolving data on new therapeutic agents and their use in combination therapy will help individualize treatment regimens while limiting adverse effects and improving compliance. Use of combination β-lactams, avibactam, tedizolid, clofazimine, bedaquiline, liposomal amikacin, and ciprofloxacin for commonly isolated species such as Mycobacterium abscessus and Mycobacterium avium complex have proven effective.SummaryFurther studies are needed to determine the incidence of NTM infection in a prospective, multicentric manner and evaluate the most promising synergistic treatment combinations in transplant recipients.

Original languageEnglish (US)
Pages (from-to)476-482
Number of pages7
JournalCurrent Opinion in Organ Transplantation
Volume24
Issue number4
DOIs
StatePublished - Aug 1 2019

    Fingerprint

Keywords

  • Mycobacterium abscessus
  • Mycobacterium avium complex
  • new antimycobacterial agents
  • nontuberculous mycobacteria
  • solid organ transplant

ASJC Scopus subject areas

  • Immunology and Allergy
  • Transplantation

Cite this